San Diego, CA, United States
San Diego, CA, United States

Time filter

Source Type

MarketStudyReport.com adds “Global Lung Cancer Therapeutics Market 2016-2020” new report to its research database. The report spread across 101 pages with table and figures in it. The Report analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020. About Lung Cancer Therapeutics Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-lung-cancer-therapeutics-market-2016-2020/ The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period. The market is divided into the following segments based on geography:  - Americas - APAC - EMEA The Report Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors  - F. Hofmann-La Roche - Eli Lilly - AstraZeneca - Pfizer - Celgene Other prominent vendors  - Abbvie - Aetna - Agennix - Allergan - Amgen - ARIAD Pharmaceuticals - Astellas Pharma - Betta Pharmaceuticals - BeyondSpring Pharmaceuticals - BioNumerik Pharmaceuticals - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Celldex - CTI BioPharma - Eisai - GlaxoSmithKline - GTx - Helsinn - Hutchison Medipharma - Ionis Pharmaceuticals - Kadmon Corporation - MabVax - Merck - Novartis - NovaRx Corporation - OncoGeneX - Ono Pharmaceutical - OSE Immunotherapeutics - OSI Pharmaceuticals - Peregrine - PharmaMar - Pierre Fabre - Qiagen - Recombio - Samsung Bioepis - Sanofi - SFJ Pharmaceuticals - Spectrum Pharmaceuticals - Sumitomo Dainippon Pharma - Synta - Takeda Pharmaceuticals - Teva Pharmaceutical - Xcovery Market driver  - Growing demand for targeted therapies - For a full, detailed list, view our report  Market challenge  - Growing popularity of alternative therapeutics  - For a full, detailed list, view our report  Market trend  - Emergence of nanomedicine platform for the treatment of lung cancer - For a full, detailed list, view our report  Key questions answered in this report  - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


Karimi-Busheri F.,University of Alberta | Karimi-Busheri F.,NovaRx Corporation | Rasouli-Nia A.,University of Alberta | Mackey J.R.,University of Alberta | Weinfeld M.,University of Alberta
Breast Cancer Research | Year: 2010

Introduction: A subpopulation of cancer cells, tumor-initiating cells, is believed to be the driving force behind tumorigenesis and resistance to radiation and chemotherapy. The persistence of tumor-initiating cells may depend on altered regulation of DNA damage and checkpoint proteins, as well as a reduced propensity to undergo apoptosis or senescence.Methods: To test this hypothesis, we isolated CD24-/low/CD44+tumor-initiating cells (as mammospheres) from MCF-7 breast cancer cells grown in adherent monolayer culture, and carried out a comprehensive comparison of cell death and DNA damage response pathways prior to and after exposure to ionizing radiation in mammospheres and monolayer MCF-7 cells. Single and double-strand break repair was measured by single-cell gel electrophoresis. The latter was also examined by phosphorylation of histone H2AX and formation of 53BP1 and Rad51 foci. Apoptosis was quantified by flow-cytometric analysis of annexin V-binding and senescence was analyzed on the basis of cellular β-galactosidase activity. We employed the telomeric repeat amplification protocol to quantify telomerase activity. Expression of key DNA repair and cell cycle regulatory proteins was detected and quantified by western blot analysis.Results: Our data demonstrate that in comparison to the bulk population of MCF-7 cells (predominantly CD24+/CD44+), the MCF-7 mammosphere cells benefit from a multifaceted approach to cellular protection relative to that seen in monolayer cells, including a reduced level of reactive oxygen species, a more active DNA single-strand break repair (SSBR) pathway, possibly due to a higher level of expression of the key SSBR protein, human AP endonuclease 1 (Ape1), and a significantly reduced propensity to undergo senescence as a result of increased telomerase activity and a low level of p21 protein expression. No significant difference was seen in the rates of double-strand break repair (DSBR) between the two cell types, but DSBR in mammospheres appears to by-pass the need for H2AX phosphorylation.Conclusions: Enhanced survival of MCF-7 tumor-initiating cells in response to ionizing radiation is primarily dependent on an inherent down-regulation of the senescence pathway. Since MCF-7 cells are representative of cancer cells that do not readily undergo apoptosis, consideration of senescence pathways may play a role in targeting stem cells from such tumors. © 2010 Karimi-Busheri et al.; licensee BioMed Central Ltd.


Patent
NovaRx Corporation | Date: 2012-12-21

Methods, compositions and compounds that include a nucleic acid comprising a sequence consisting essentially of polyT/polyU and an agent that inhibits the production or activity of an immunosuppressive compound for treating tumors are described.


Patent
NovaRx Corporation | Date: 2013-03-13

Compounds that are specifically toxic to cancer stem cells are disclosed.


Patent
NovaRx Corporation | Date: 2013-03-13

Compounds that are specifically toxic to cancer stem cells are disclosed.


Patent
Novarx Corporation | Date: 2013-03-13

Compounds that are specifically toxic to cancer stem cells are disclosed.


Patent
NovaRx Corporation | Date: 2013-03-13

Compounds that are specifically toxic to cancer stem cells are disclosed.


Patent
NovaRx Corporation | Date: 2013-03-13

Compounds that are specifically toxic to cancer stem cells are disclosed.


A universal vaccine containing a mixture of allogeneic cell lines, including tumor stem cells, effective against tumors regardless of type is disclosed. The cell lines are also modified to prevent interference with the immune response by any immunosuppressive agents they may secrete.


Patent
Novarx Corporation | Date: 2012-05-11

The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or non-response of pretested populations of subjects.

Loading NovaRx Corporation collaborators
Loading NovaRx Corporation collaborators